Tofacitinib and Current Research 2014

Discussion in 'Everything Else' started by edia, Aug 13, 2014.

  1. edia

    edia New Member

    Hi, I'm new here, so apologies if this has already been covered, but I couldn't find an existing discussion on the topic.

    Has anyone else been following the research being done by Dr. Angela Christiano's team at Columbia University? It seems they've made solid progress in understanding hair loss. Her team found that the genetic profile for hair loss shares many similarities with inflammatory, autoimmune disorders like Type 1 diabetes, celiac disease and rheumatoid arthritis and NOT psoriasis and other skin conditions, as previously believed.

    There's also been early success in treating alopecia in a clinical setting based on these new findings. A dermatologist at Yale, Dr. Brett King, treated a male patient with alopecia universalis using Tofacitinib (a/k/a Xeljanz), a rheumatoid arthritis drug, with impressive results. Dr. King's approach came out of Dr. Christiano's research. Her team had used tofacitinib and ruxolitinib to reverse alopecia areata in mice.

    It should be noted that there are serious side effects associated with Tofacitinib. It's a powerful immunosuppressant and increases the risk for liver damage and cancer, among other things. While it is FDA approved in the US for rheumatoid arthritis, it was rejected in the EU because of these risks.

    Maybe there are nutritional approaches worth trying in the interim? There's a wealth of information on anti-inflammatory diets, and even people who claim that they've cured rheumatoid arthritis through diet.

    It's still early days, obviously, but hopeful nonetheless.